# Meydan Lab — Cem Meydan > Website of the Meydan Lab at Weill Cornell Medicine. Principal Investigator: Dr. Cem Meydan. The Meydan Lab combines multiomics, machine learning, and statistical modeling to study gene regulation, lymphoma biology, and human physiology. Research spans chromatin and 3D genome organization, spatial tissue biology, and inflammatory and metabolic responses. A projects page describes each project; a contributions page documents individual contributions, findings and primary sources. Content reviewed 2026-10-31. ## Summary - Who: Cem Meydan, PhD is a computational biologist and Assistant Professor of Research in Systems and Computational Biomedicine at Weill Cornell Medicine, and Principal Investigator of the Meydan Lab. His faculty appointment was previously in Hematology and Medical Oncology (Department of Medicine). - Research: The Meydan Lab at Weill Cornell Medicine studies lymphoma genomics, chromatin regulation, and spatial and single-cell biology. Methodological research develops machine-learning and statistical approaches for molecular data integration and biological modeling. Research also examines inflammatory and metabolic responses through host proteomics, spaceflight studies, and host–microbiome questions. - Research areas: Lymphoma Genomics & Chromatin Regulation; AI & Statistical Modeling; Spatial & Single-Cell Biology; Inflammation & Metabolism. - Wider record: Dr. Meydan’s wider research record includes the NASA Twins Study, SOMA, mechanistic studies of enasidenib, rapid RT-LAMP testing and host-response research during New York’s first COVID-19 wave, and urban microbiome mapping. His entrepreneurial work includes GutBio development at Onegevity and research leadership at Thorne HealthTech. The linked study accounts retain individual contributions, historical context, sources, and resources. - Publications: 165 items in the bibliography (101 journal articles); first or shared-first author on 15 and corresponding or co-corresponding author on 5. Venues include Nature, Science, Cell, Nature Medicine, Cancer Cell and Cancer Discovery. - Leadership: led the computational analyses and data curation of the 2026 Nature SWI/SNF–CTCF study (co-first and co-corresponding author); co-corresponding author of SOMA (Nature 2024); co-led Inspiration4 and NASA Twins Study data acquisition and sharing (per Wu et al., Nature Communications 2024); leads and supervises computational and statistical work in collaborative studies with Weill Cornell laboratories and international consortia. - Applications: mechanism of an approved therapy (preclinical epigenomic evidence cited by the clinical development of enasidenib, FDA approval 2017); named co-inventor on an international patent application for SMARCA2/SMARCA4 inhibition in lymphoma (WO2025096976A1); rapid RT-LAMP testing during New York's first COVID-19 wave (spring 2020), before fully at-home self-testing was available in the United States, whose validation contributed to Color's FDA emergency authorization in May 2020; public data portals (SOMA, COVID Genes, MetaSUB map). - Media: 109 archived news items from 60 outlets, 2013–2026, 21 of which name Dr. Meydan; outlets include The New York Times, Science, National Geographic, CNN, The Wall Street Journal, MIT Technology Review, Medical Xpress, Weill Cornell Medicine. Earlier coverage (subway microbiome, NASA Twins) dates from his scientist years at Weill Cornell, often alongside Dr. Christopher Mason. The Independent later rewrote its June 11, 2024 SOMA story into a UK-focused piece that no longer names Dr. Meydan; the archived copy keeps the original version. - Ventures (separate from the lab): founding employee at Onegevity (GutBio microbiome test), research and microbiome product leadership at Thorne HealthTech, co-founder of ARQ. ## Key facts - Cem Meydan, PhD: Assistant Professor of Research in Systems and Computational Biomedicine, Weill Cornell Medicine. Principal Investigator of the Meydan Lab. - SWI/SNF, CTCF and the 3D genome (Nature 2026): shared first and shared corresponding author; led computational analyses and data curation. - SOMA, the Space Omics and Medical Atlas (Nature 2024): shared corresponding author. - NASA Twins Study (Science 2019) and spaceflight mitochondrial stress (Cell 2020): one of several equal-contribution first authors. - ARID1A in lymphoma (Cancer Cell 2024): shared first author; named co-inventor on the resulting international patent application WO2025096976A1 (a published application). - Applied work: preclinical mechanism research for the leukemia drug enasidenib (Cancer Discovery 2017, shared first author) and a rapid RT-LAMP SARS-CoV-2 test from spring 2020 (Nature Communications 2021, shared first author). - Context: many studies were collaborations with other Weill Cornell laboratories (including the Mason and Melnick labs) and international consortia; each record states Dr. Meydan’s own role. Onegevity/Thorne HealthTech (founding employee) and ARQ (co-founder) are ventures, separate from the lab and Weill Cornell Medicine. ## Main content - [Research](https://www.cemmeydan.com/#research): The four current research areas. - [Projects](https://www.cemmeydan.com/projects/): Aims, approach, key findings, portals, code, data and publications of each project, plus ventures (separate from the lab). - [Selected work](https://www.cemmeydan.com/#selected-work): Chromatin remodeling and lymphoma; an integrated view of human spaceflight; enasidenib mechanism and clinical development; rapid molecular testing during New York's first COVID-19 wave. - [Publications](https://www.cemmeydan.com/publications/): Complete bibliography of publications coauthored by Cem Meydan, with search, filters, authorship roles and DOI links (static HTML without JavaScript). - [Resources](https://www.cemmeydan.com/projects/#resources): Portals, code, data and access routes. - [Media](https://www.cemmeydan.com/#media): Four recent coverage highlights. - [Media archive](https://www.cemmeydan.com/media/): All press coverage by study, with dates, outlets, original and archived links. - [Contact](https://www.cemmeydan.com/#contact): Collaboration contact and the current opening. ## Contributions and sources - [Contributions and sources](https://www.cemmeydan.com/evidence/): The full account of each selected-work group (historical context, findings, Dr. Meydan's contribution per paper, primary sources with locators), earlier urban microbiome research, and research resources. - [Ventures: entrepreneurship and product development](https://www.cemmeydan.com/evidence/#entrepreneurship): Founding employee of Onegevity (GutBio product and analytical platform), research leadership at Thorne HealthTech, co-founder of ARQ. - [Plain-text contributions and sources](https://www.cemmeydan.com/evidence.md) - [Selected collaborative research funding & support](https://www.cemmeydan.com/research/funding/): Competitively funded programs (NIH, Blood Cancer United/LLS, NASA, Cancer Grand Challenges and others) to which Dr. Meydan has contributed computational and multi-omic expertise, with each award's principal investigators, his role, sources and selected coauthored outputs. [Markdown](https://www.cemmeydan.com/research/funding.md) · [JSON](https://www.cemmeydan.com/data/funding.json) ## Structured public records - [Profile](https://www.cemmeydan.com/data/profile.json) - [Evidence](https://www.cemmeydan.com/data/evidence.json) - [Publications](https://www.cemmeydan.com/data/publications.json) - [Research funding and collaborations](https://www.cemmeydan.com/data/funding.json) - [Media coverage](https://www.cemmeydan.com/media-archive/media.json) · [Markdown](https://www.cemmeydan.com/media-archive/media.md)